Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 Jun;58(6):1620–1627. doi: 10.1128/iai.58.6.1620-1627.1990

Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.

C O Tacket 1, B Forrest 1, R Morona 1, S R Attridge 1, J LaBrooy 1, B D Tall 1, M Reymann 1, D Rowley 1, M M Levine 1
PMCID: PMC258689  PMID: 1692807

Abstract

A live oral vaccine consisting of attenuated Salmonella typhi Ty21a expressing Vibrio cholerae O1 Inaba lipopolysaccharide (LPS) O antigen was constructed and tested in volunteers for safety, immunogenicity, and efficacy. Fourteen adults ingested three doses of 10(10) viable organisms with buffer. One month later, 8 vaccinees and 13 unimmunized controls were challenged with 10(6) pathogenic V. cholerae O1 E1 T or Inaba organisms. No significant adverse reactions to vaccination were observed. All volunteers had significant rises in serum immunoglobulin G (IgG) antibody to S. typhi LPS. Only 2 (14%) of 14 had significant rises in serum IgA or IgG antibody to Inaba LPS, and 5 (36%) of 14 had fourfold rises in vibriocidal antibody. In the challenge study, diarrhea occurred in 13 of 13 controls and 6 of 8 vaccinees (vaccine efficacy, 25%; P = 0.13). The vaccine significantly reduced the severity of the clinical illness (P less than 0.05) and caused decreased excretion of challenge vibrios (P less than 0.05). Although the typhoid-cholera hybrid vaccine did not provide significant protection overall against experimental cholera, this study demonstrates the importance of antibody to V. cholerae O antigen in ameliorating clinical illness and illustrates the use of an S. typhi carrier vaccine strain expressing a foreign antigen.

Full text

PDF
1620

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attridge S. R., Rowley D. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae. J Infect Dis. 1983 Nov;148(5):931–939. doi: 10.1093/infdis/148.5.931. [DOI] [PubMed] [Google Scholar]
  2. Baron L. S., Kopecko D. J., Formal S. B., Seid R., Guerry P., Powell C. Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a. Infect Immun. 1987 Nov;55(11):2797–2801. doi: 10.1128/iai.55.11.2797-2801.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Belfort M., Maley G. F., Maley F. Characterization of the Escherichia coli thyA gene and its amplified thymidylate synthetase product. Proc Natl Acad Sci U S A. 1983 Apr;80(7):1858–1861. doi: 10.1073/pnas.80.7.1858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Belfort M., Maley G., Pedersen-Lane J., Maley F. Primary structure of the Escherichia coli thyA gene and its thymidylate synthase product. Proc Natl Acad Sci U S A. 1983 Aug;80(16):4914–4918. doi: 10.1073/pnas.80.16.4914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benenson A. S., Mosley W. H., Fahimuddin M., Oseasohn R. O. Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field. Bull World Health Organ. 1968;38(3):359–372. [PMC free article] [PubMed] [Google Scholar]
  6. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987 Jun;155(6):1260–1265. doi: 10.1093/infdis/155.6.1260. [DOI] [PubMed] [Google Scholar]
  7. Cash R. A., Music S. I., Libonati J. P., Craig J. P., Pierce N. F., Hornick R. B. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis. 1974 Oct;130(4):325–333. doi: 10.1093/infdis/130.4.325. [DOI] [PubMed] [Google Scholar]
  8. Clemens J. D., Sack D. A., Harris J. R., Chakraborty J., Khan M. R., Stanton B. F., Kay B. A., Khan M. U., Yunus M., Atkinson W. Field trial of oral cholera vaccines in Bangladesh. Lancet. 1986 Jul 19;2(8499):124–127. doi: 10.1016/s0140-6736(86)91944-6. [DOI] [PubMed] [Google Scholar]
  9. Clements J. D., El-Morshidy S. Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun. 1984 Nov;46(2):564–569. doi: 10.1128/iai.46.2.564-569.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clements M. L., Levine M. M., Young C. R., Black R. E., Lim Y. L., Robins-Browne R. M., Craig J. P. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982 Apr;145(4):465–473. doi: 10.1093/infdis/145.4.465. [DOI] [PubMed] [Google Scholar]
  11. Curtiss R., 3rd, Goldschmidt R. M., Fletchall N. B., Kelly S. M. Avirulent Salmonella typhimurium delta cya delta crp oral vaccine strains expressing a streptococcal colonization and virulence antigen. Vaccine. 1988 Apr;6(2):155–160. doi: 10.1016/s0264-410x(88)80020-3. [DOI] [PubMed] [Google Scholar]
  12. Curtiss R., 3rd, Kelly S. M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun. 1987 Dec;55(12):3035–3043. doi: 10.1128/iai.55.12.3035-3043.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Czerkinsky C. C., Nilsson L. A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983 Dec 16;65(1-2):109–121. doi: 10.1016/0022-1759(83)90308-3. [DOI] [PubMed] [Google Scholar]
  14. Edwards M. F., Stocker B. A. Construction of delta aroA his delta pur strains of Salmonella typhi. J Bacteriol. 1988 Sep;170(9):3991–3995. doi: 10.1128/jb.170.9.3991-3995.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ferreccio C., Levine M. M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis. 1989 Apr;159(4):766–769. doi: 10.1093/infdis/159.4.766. [DOI] [PubMed] [Google Scholar]
  16. Forrest B. D. Identification of an intestinal immune response using peripheral blood lymphocytes. Lancet. 1988 Jan 16;1(8577):81–83. doi: 10.1016/s0140-6736(88)90284-x. [DOI] [PubMed] [Google Scholar]
  17. Forrest B. D., LaBrooy J. T., Attridge S. R., Boehm G., Beyer L., Morona R., Shearman D. J., Rowley D. Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans. J Infect Dis. 1989 Jan;159(1):145–146. doi: 10.1093/infdis/159.1.145. [DOI] [PubMed] [Google Scholar]
  18. Germanier R., Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975 May;131(5):553–558. doi: 10.1093/infdis/131.5.553. [DOI] [PubMed] [Google Scholar]
  19. Gilman R. H., Hornick R. B., Woodard W. E., DuPont H. L., Snyder M. J., Levine M. M., Libonati J. P. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis. 1977 Dec;136(6):717–723. doi: 10.1093/infdis/136.6.717. [DOI] [PubMed] [Google Scholar]
  20. Glass R. I., Becker S., Huq M. I., Stoll B. J., Khan M. U., Merson M. H., Lee J. V., Black R. E. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol. 1982 Dec;116(6):959–970. doi: 10.1093/oxfordjournals.aje.a113498. [DOI] [PubMed] [Google Scholar]
  21. Glass R. I., Svennerholm A. M., Khan M. R., Huda S., Huq M. I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–242. doi: 10.1093/infdis/151.2.236. [DOI] [PubMed] [Google Scholar]
  22. Gotuzzo E., Morris J. G., Jr, Benavente L., Wood P. K., Levine O., Black R. E., Levine M. M. Association between specific plasmids and relapse in typhoid fever. J Clin Microbiol. 1987 Sep;25(9):1779–1781. doi: 10.1128/jcm.25.9.1779-1781.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hisatsune K., Kondo S., Kawata T., Kishimoto Y. Fatty acid composition of lipopolysaccharides of Vibrio cholerae 35A3 (Inaba), NIB 90 (Ogawa), and 4715 (Nag). J Bacteriol. 1979 Apr;138(1):288–290. doi: 10.1128/jb.138.1.288-290.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hoiseth S. K., Stocker B. A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981 May 21;291(5812):238–239. doi: 10.1038/291238a0. [DOI] [PubMed] [Google Scholar]
  25. Holmgren J., Svennerholm A. M. Enzyme-linked immunosorbent assays for cholera serology. Infect Immun. 1973 May;7(5):759–763. doi: 10.1128/iai.7.5.759-763.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Holmgren J., Svennerholm A. M., Lönnroth I., Fall-Persson M., Markman B., Lundbeck H. Development of improved cholera vaccine based on subunit toxoid. Nature. 1977 Oct 13;269(5629):602–604. doi: 10.1038/269602a0. [DOI] [PubMed] [Google Scholar]
  27. Holmgren J., Svennerholm A. M. Mechanisms of disease and immunity in cholera: a review. J Infect Dis. 1977 Aug;136 (Suppl):S105–S112. doi: 10.1093/infdis/136.supplement.s105. [DOI] [PubMed] [Google Scholar]
  28. Hone D. M., Attridge S. R., Forrest B., Morona R., Daniels D., LaBrooy J. T., Bartholomeusz R. C., Shearman D. J., Hackett J. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun. 1988 May;56(5):1326–1333. doi: 10.1128/iai.56.5.1326-1333.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hone D., Attridge S., van den Bosch L., Hackett J. A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains. Microb Pathog. 1988 Dec;5(6):407–418. doi: 10.1016/0882-4010(88)90002-2. [DOI] [PubMed] [Google Scholar]
  30. Kabir S. Characterization of the lipopolysaccharide from Vibrio cholerae 395 (Ogawa). Infect Immun. 1982 Dec;38(3):1263–1272. doi: 10.1128/iai.38.3.1263-1272.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kantele A. M., Takanen R., Arvilommi H. Immune response to acute diarrhea seen as circulating antibody-secreting cells. J Infect Dis. 1988 Nov;158(5):1011–1016. doi: 10.1093/infdis/158.5.1011. [DOI] [PubMed] [Google Scholar]
  32. Kaper J. B., Lockman H., Baldini M. M., Levine M. M. Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature. 1984 Apr 12;308(5960):655–658. doi: 10.1038/308655a0. [DOI] [PubMed] [Google Scholar]
  33. Kenne L., Lindberg B., Unger P., Gustafsson B., Holme T. Structural studies of the Vibrio cholerae O-antigen. Carbohydr Res. 1982 Mar 1;100:341–349. doi: 10.1016/s0008-6215(00)81047-2. [DOI] [PubMed] [Google Scholar]
  34. Levine M. M., Black R. E., Clements M. L., Cisneros L., Nalin D. R., Young C. R. Duration of infection-derived immunity to cholera. J Infect Dis. 1981 Jun;143(6):818–820. doi: 10.1093/infdis/143.6.818. [DOI] [PubMed] [Google Scholar]
  35. Levine M. M., Black R. E., Clements M. L., Lanata C., Sears S., Honda T., Young C. R., Finkelstein R. A. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun. 1984 Feb;43(2):515–522. doi: 10.1128/iai.43.2.515-522.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Levine M. M., Ferreccio C., Black R. E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987 May 9;1(8541):1049–1052. doi: 10.1016/s0140-6736(87)90480-6. [DOI] [PubMed] [Google Scholar]
  37. Levine M. M., Kaper J. B., Black R. E., Clements M. L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev. 1983 Dec;47(4):510–550. doi: 10.1128/mr.47.4.510-550.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  39. Levine M. M., Kaper J. B., Herrington D., Losonsky G., Morris J. G., Clements M. L., Black R. E., Tall B., Hall R. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun. 1988 Jan;56(1):161–167. doi: 10.1128/iai.56.1.161-167.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Levine M. M., Taylor D. N., Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J. 1989 Jun;8(6):374–381. doi: 10.1097/00006454-198906000-00010. [DOI] [PubMed] [Google Scholar]
  41. Levine M. M., Young C. R., Black R. E., Takeda Y., Finkelstein R. A. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol. 1985 Feb;21(2):174–179. doi: 10.1128/jcm.21.2.174-179.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Maher K. O., Morris J. G., Jr, Gotuzzo E., Ferreccio C., Ward L. R., Benavente L., Black R. E., Rowe B., Levine M. M. Molecular techniques in the study of Salmonella typhi in epidemiologic studies in endemic areas: comparison with Vi phage typing. Am J Trop Med Hyg. 1986 Jul;35(4):831–835. doi: 10.4269/ajtmh.1986.35.831. [DOI] [PubMed] [Google Scholar]
  43. Manning P. A., Heuzenroeder M. W., Yeadon J., Leavesley D. I., Reeves P. R., Rowley D. Molecular cloning and expression in Escherichia coli K-12 of the O antigens of the Inaba and Ogawa serotypes of the Vibrio cholerae O1 lipopolysaccharides and their potential for vaccine development. Infect Immun. 1986 Aug;53(2):272–277. doi: 10.1128/iai.53.2.272-277.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Mekalanos J. J., Swartz D. J., Pearson G. D., Harford N., Groyne F., de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature. 1983 Dec 8;306(5943):551–557. doi: 10.1038/306551a0. [DOI] [PubMed] [Google Scholar]
  45. Mosley W. H., Aziz K. M., Rahman A. S., Chowdhury A. K., Ahmed A. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation. Bull World Health Organ. 1973;49(4):381–387. [PMC free article] [PubMed] [Google Scholar]
  46. Mosley W. H., Benenson A. S., Barui R. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ. 1968;38(3):327–334. [PMC free article] [PubMed] [Google Scholar]
  47. Mosley W. H., Benenson A. S., Barui R. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. Bull World Health Organ. 1968;38(3):335–346. [PMC free article] [PubMed] [Google Scholar]
  48. Mosley W. H., McCormack W. M., Ahmed A., Chowdhury A. K., Barui R. K. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ. 1969;40(2):187–197. [PMC free article] [PubMed] [Google Scholar]
  49. Murphy J. R., Baqar S., Muñoz C., Schlesinger L., Ferreccio C., Lindberg A. A., Svenson S., Losonsky G., Koster F., Levine M. M. Characteristics of humoral and cellular immunity to Salmonella typhi in residents of typhoid-endemic and typhoid-free regions. J Infect Dis. 1987 Dec;156(6):1005–1009. doi: 10.1093/infdis/156.6.1005. [DOI] [PubMed] [Google Scholar]
  50. Murray B. E., Levine M. M., Cordano A. M., D'Ottone K., Jayanetra P., Kopecko D., Pan-Urae R., Prenzel I. Survey of plasmids in Salmonella typhi from Chile and Thailand. J Infect Dis. 1985 Mar;151(3):551–555. doi: 10.1093/infdis/151.3.551. [DOI] [PubMed] [Google Scholar]
  51. Nalin D. R., Levine M. M., Hornick R. B., Bergquist E. J., Hoover D., Holley H. P., Waterman D., VanBlerk J., Matheny S., Sotman S. The problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera. Trans R Soc Trop Med Hyg. 1979;73(1):10–14. doi: 10.1016/0035-9203(79)90120-2. [DOI] [PubMed] [Google Scholar]
  52. Neoh S. H., Rowley D. Protection of infant mice against cholera by antibodies to three antigens of Vibrio cholerae. J Infect Dis. 1972 Jul;126(1):41–47. doi: 10.1093/infdis/126.1.41. [DOI] [PubMed] [Google Scholar]
  53. Neoh S. H., Rowley D. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J Infect Dis. 1970 May;121(5):505–513. doi: 10.1093/infdis/121.5.505. [DOI] [PubMed] [Google Scholar]
  54. Peterson J. W. Protection against experimental cholera by oral or parenteral immunization. Infect Immun. 1979 Nov;26(2):594–598. doi: 10.1128/iai.26.2.594-598.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Rennels M. B., Levine M. M., Daya V., Angle P., Young C. Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J Infect Dis. 1980 Sep;142(3):328–331. doi: 10.1093/infdis/142.3.328. [DOI] [PubMed] [Google Scholar]
  56. Resnick I. G., Ford C. W., Shackleford G. M., Berry L. J. Improved protection against cholera in adult rabbits with a combined flagellar-toxoid vaccine. Infect Immun. 1980 Nov;30(2):375–380. doi: 10.1128/iai.30.2.375-380.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Rowley D. Immune responses to enterobacteria presented by various routes. Prog Allergy. 1983;33:159–174. [PubMed] [Google Scholar]
  58. Sadoff J. C., Ballou W. R., Baron L. S., Majarian W. R., Brey R. N., Hockmeyer W. T., Young J. F., Cryz S. J., Ou J., Lowell G. H. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 1988 Apr 15;240(4850):336–338. doi: 10.1126/science.3281260. [DOI] [PubMed] [Google Scholar]
  59. Sarasombath S., Banchuin N., Sukosol T., Vanadurongwan S., Rungpitarangsi B., Dumavibhat B. Systemic and intestinal immunities after different typhoid vaccinations. Asian Pac J Allergy Immunol. 1987 Jun;5(1):53–61. [PubMed] [Google Scholar]
  60. Sears S. D., Richardson K., Young C., Parker C. D., Levine M. M. Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun. 1984 May;44(2):439–444. doi: 10.1128/iai.44.2.439-444.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Seid R. C., Jr, Kopecko D. J., Sadoff J. C., Schneider H., Baron L. S., Formal S. B. Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J Biol Chem. 1984 Jul 25;259(14):9028–9034. [PubMed] [Google Scholar]
  62. Stocker B. A. Auxotrophic Salmonella typhi as live vaccine. Vaccine. 1988 Apr;6(2):141–145. doi: 10.1016/s0264-410x(88)80017-3. [DOI] [PubMed] [Google Scholar]
  63. Svennerholm A. M., Holmgren J. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun. 1976 Mar;13(3):735–740. doi: 10.1128/iai.13.3.735-740.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Tacket C. O., Ferreccio C., Robbins J. B., Tsai C. M., Schulz D., Cadoz M., Goudeau A., Levine M. M. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis. 1986 Aug;154(2):342–345. doi: 10.1093/infdis/154.2.342. [DOI] [PubMed] [Google Scholar]
  65. Tagliabue A., Nencioni L., Caffarena A., Villa L., Boraschi D., Cazzola G., Cavalieri S. Cellular immunity against Salmonella typhi after live oral vaccine. Clin Exp Immunol. 1985 Nov;62(2):242–247. [PMC free article] [PubMed] [Google Scholar]
  66. Tagliabue A., Villa L., Boraschi D., Peri G., de Gori V., Nencioni L. Natural anti-bacterial activity against Salmonella typhi by human T4+ lymphocytes armed with IgA antibodies. J Immunol. 1985 Dec;135(6):4178–4182. [PubMed] [Google Scholar]
  67. Targan S. R., Kagnoff M. F., Brogan M. D., Shanahan F. Immunologic mechanisms in intestinal diseases. Ann Intern Med. 1987 Jun;106(6):853–870. doi: 10.7326/0003-4819-106-6-853. [DOI] [PubMed] [Google Scholar]
  68. Wahdan M. H., Sérié C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982 Mar;145(3):292–295. doi: 10.1093/infdis/145.3.292. [DOI] [PubMed] [Google Scholar]
  69. Ward H. M., Morelli G., Kamke M., Morona R., Yeadon J., Hackett J. A., Manning P. A. A physical map of the chromosomal region determining O-antigen biosynthesis in Vibrio cholerae O1. Gene. 1987;55(2-3):197–204. doi: 10.1016/0378-1119(87)90280-0. [DOI] [PubMed] [Google Scholar]
  70. Welliver R. C., Ogra P. L. Importance of local immunity in enteric infection. J Am Vet Med Assoc. 1978 Sep 1;173(5 Pt 2):560–564. [PubMed] [Google Scholar]
  71. Yamamoto T., Tamura Y., Yokota T. Enteroadhesion fimbriae and enterotoxin of Escherichia coli: genetic transfer to a streptomycin-resistant mutant of the galE oral-route live-vaccine Salmonella typhi Ty21a. Infect Immun. 1985 Dec;50(3):925–928. doi: 10.1128/iai.50.3.925-928.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES